TIDMSBTX
RNS Number : 3346L
SkinBioTherapeutics PLC
05 September 2023
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
SkinBioTherapeutics identifies blends for use in new consumer
study into acne
-- Two new formulas to be trialled side-by-side to compare
efficacy against the most common skin condition
-- Study to be conducted in partnership with Winclove Probiotics
-- Consumer study on track to commence in Q4 2023
5 September 2023 - SkinBioTherapeutics plc (AIM: SBTX, or the
Company), the life science business focused on skin health, has
announced that it has chosen the probiotic blends it will use for
the comparative studies for its consumer study in acne.
The two separate blends will be tested side-by-side in a
consumer volunteer study to determine which has better efficacy.
The Company is aiming to target the inflammatory pathways that are
associated with irritable skin conditions like acne. The blends
will be supplied to participants in powder-form for the study,
however this may not be the final formulation form for a potential
commercial product.
An independent third-party will conduct the study and run two
separate cohorts in parallel to compare the efficacy of the
respective formulas, which are being provided by Dutch food
supplement provider Winclove Probiotics BV.
The study is expected to commence in Q4 2023 and be complete by
year end with results issued thereafter. Further details of the
study will be disclosed by the end of Q3 2023. The benefit of
undertaking a consumer study is the relatively short time and cost
compared to a clinical study.
SkinBioTherapeutics has previously developed and marketed
AxisBiotix PS(TM) - a probiotic food supplement for the treatment
of psoriasis - which has strong consumer retention levels and is
reported to be highly effective by users. The new acne formulation
will be produced in a similar powder format to be taken daily, like
AxisBiotix PS.
Acne is a skin condition that develops when pores get clogged
with dead skin, bacteria, and dried skin oil buildup, which leads
to redness, tenderness, pimples, nodules, or cysts primarily on the
face, back, or chest. It can range from mild to severe and
typically affects teenagers and young adults but anyone can be
affected. Acne is thought to be caused by overactive oil glands, a
slower cell shedding process, and higher levels of certain bacteria
causing inflammation.
Up to 85% of people will suffer from acne at some point in their
life. Although not life-threatening, acne can cause irritation and
life-long scarring, and can negatively impact a person's mental
health and self-esteem.
The strong desire to alleviate the symptoms makes the global
acne market worth $9.4billion with CAGR of 4.8% (fortune business
insights 2019). The UK acne therapeutics market size is at around
$261 Mn in 2022 and is projected to reach $377 Mn in 2030,
exhibiting a CAGR of 4.7%. 34 % of adults in the UK have
experienced acne at some time in their lives and 11.5% of adults
presently have acne. Overall, this means that acne is the most
common skin condition and one of the top 10 most prevalent diseases
worldwide.
Doctors currently treat severe acne with topical steroid creams,
although oral medications can also be used. However, steroid
medications can lead to undesirable side effects, including skin
dryness, irritation, and rashes. Side effects from oral medications
can be more severe such as depression or suicidal thoughts.
Stuart Ashman, CEO of SkinBioTherapeutics, said:
"There is an enormous market for acne treatment that we are
eager to enter, and to provide those who struggle with the
condition with a microbiome-based product that has the potential to
alleviate their symptoms. The use of probiotic treatments for acne
is relatively novel but could hold some major advantages over
current treatments.
"Identifying the two blends we intend to use is another step
forward in the preparation for our study in acne later this year.
We have shown we can develop and commercialise products with the
first being AxisBiotix-Ps(TM) which is now launched in three
countries. An AxisBiotix programme for acne w ill be our second
commercial product . We have learnt a lot from our first product
development and launch; we are in a good position for the next
one.
"We eagerly anticipate commencing and seeing the results of this
study with a view to bringing a new formula to market ."
-Ends-
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 191 495 7325
Stuart J . Ashman, CEO
Manprit Randhawa, CFO
Cenkos Securities Plc (Nominated Tel: +44 (0) 20 7397 8900
Adviser & Broker)
Giles Balleny, Max Gould (Corporate
Finance)
Dale Bellis, Tamar Cranford-Smith
(Sales)
Instinctif Partners (financial Tel: +44 (0) 20 7457 2020
press) SkinBioT herapeutics @instinctif.com
Melanie Toyne-Sewell / Tim Field
/ Adam Loudon
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by Professor
Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors,
the most advanced of which are cosmetic skincare and food
supplements to modulate the immune system by harnessing the
gut-skin axis. In each area SkinBioTherapeutics plans to exemplify
its technology through human studies. The Company's first product,
AxisBiotix-Ps(TM), a food supplement to address the symptoms of
mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in
Newcastle, UK. For more information, visit: www.skinbiotix.com and
www.axisbiotix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDQZLFBXKLEBBB
(END) Dow Jones Newswires
September 05, 2023 02:00 ET (06:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2023 to Apr 2024
